

| Drug Name                 | Participating Drug Company                                     | Commonly Treated Conditions   | Agreed to Negotiated Price for 30-day Supply for CY 2027 | List Price for 30-day Supply, CY 2024 | Discount of Negotiated Price from 2024 List Price | Total Part D Gross Covered Prescription Drug Costs, CY 2024 | Number of Medicare Part D Enrollees Who Used the Drug, CY 2024 |
|---------------------------|--|---|--|---------------------------------------|---|---|--|
| Ozempic; Rybelsus; Wegovy | Novo Nordisk Inc.  | Type 2 diabetes; Type 2 diabetes and cardiovascular disease; Cardiovascular disease and obesity/ overweight | \$274  | \$959                                 | 71%   | \$15,161,908,000  | 2,282,000  |
| Trelegy Ellipta           | GlaxoSmithKline Intellectual Property Development Ltd. England | Asthma; Chronic obstructive pulmonary disease   | \$175  | \$654                                 | 73%   | \$5,296,660,000   | 1,269,000  |
| Xtandi                    | Astellas Pharma US, Inc.                                       | Prostate cancer   | \$7,004  | \$13,480                              | 48%   | \$3,401,099,000   | 35,000   |
| Pomalyst                  | Bristol-Myers Squibb Company                                   | Kaposi sarcoma; Multiple myeloma  | \$8,650  | \$21,744                              | 60%   | \$2,150,644,000   | 14,000   |
| Ofev                      | Boehringer Ingelheim Pharmaceuticals, Inc.                     | Idiopathic pulmonary fibrosis   | \$6,350  | \$12,622                              | 50%   | \$2,087,330,000   | 24,000   |
| Ibrance                   | Pfizer Inc.  | Breast cancer   | \$7,871  | \$15,741                              | 50%   | \$2,036,178,000   | 16,000   |
| Linzess                   | AbbVie Inc.  | Chronic idiopathic constipation; Irritable bowel syndrome with constipation                                 | \$136  | \$539                                 | 75%   | \$1,982,587,000   | 632,000  |
| Calquence                 | AstraZeneca UK Limited   | Chronic lymphocytic leukemia/small lymphocytic lymphoma; Mantle cell lymphoma                               | \$8,600  | \$14,228                              | 40%   | \$1,703,116,000   | 15,000   |
| Austedo; Austedo XR       | Teva Branded Pharmaceutical Products R&D LLC                   | Chorea in Huntington's disease; Tardive dyskinesia  | \$4,093  | \$6,623                               | 38%   | \$1,675,176,000   | 27,000   |
| Breo Ellipta              | GlaxoSmithKline Intellectual Property Development Ltd. England | Asthma; Chronic obstructive pulmonary disease   | \$67   | \$397                                 | 83%   | \$1,428,106,000   | 626,000  |
| Xifaxan                   | Salix Pharmaceuticals Inc.                                     | Hepatic encephalopathy; Irritable bowel syndrome with diarrhea  | \$1,000  | \$2,696                               | 63%   | \$1,158,988,000   | 105,000  |
| Vraylar                   | AbbVie Inc.  | Bipolar I disorder; Major depressive disorder; Schizophrenia  | \$770  | \$1,376                               | 44%   | \$1,136,814,000   | 118,000  |
| Tradjenta                 | Boehringer Ingelheim Pharmaceuticals, Inc.                     | Type 2 diabetes   | \$78   | \$488                                 | 84%   | \$1,128,335,000   | 274,000  |
| Janumet; Janumet XR       | Merck Sharp & Dohme LLC  | Type 2 diabetes   | \$80   | \$526                                 | 85%   | \$1,067,594,000   | 239,000  |
| Otezla; Otezla XR         | Amgen Inc.   | Oral ulcers in Behçet's Disease; Plaque psoriasis; Psoriatic arthritis                                      | \$1,650  | \$4,722                               | 65%   | \$1,045,443,000   | 31,000   |